Finally, exogenous DLL4 or leniolisib, a PI3Kδ/AKT inhibitor, were shown to prevent the aberrant PAH-like endothelial phenotype associated with BMPR2 loss. Here, BMPR2 is linked to pulmonary arterial hypertension.